Search for the best prices     on the Internet!

Preface
I Molecular Biology of Renal Cell Carcinoma 1
1 Classification of Renal Cell Carcinoma Based on Morphologic and Cytogenetic Correlations 3
2 Molecular Cytogenetic Stratification of Renal Cell Tumors 13
3 Oncogenes in Renal Cell Carcinoma 26
4 Molecular Studies of the VHL Tumor Suppressor Gene in Renal Cell Carcinoma 33
5 The Cloning of Tumor Suppressor Genes from the Short Arm of Human Chromosome 3 that Play a Role in the Development of Renal Cell Carcinoma 40
6 Expression of the Wilms' Tumor Suppressor Gene (WT1) in Renal Cell Carcinoma 56
II Immunology of Renal Cell Carcinoma 63
7 Alterations in Signal Transduction in T Cells from Cancer Patients 65
8 Impaired Signal Transduction in Tumor Infiltrating T Cells from Patients with Renal Cell Carcinoma
9 Recruitment of MHC-Restricted Cytotoxic T Lymphocytes Specific for Renal Cell Carcinoma to the Tumor In Situ 84
10 T-Lymphocyte Response in Renal Cell Carcinoma 94
11 Adhesion Molecules in Renal Cell Carcinoma 106
III Novel Therapeutic Approaches in Renal Cell Carcinoma 119
A Genetic Manipulation 121
12 Cellular and Molecular Considerations for the Treatment of Murine Renal Cancer
13 2-5A-Antisense: A Novel Approach to Cancer Therapy
14 Analysis of Immune Response Induced by Tumors Engineered to Secrete Cytokines 149
15 New Avenues of Cancer Treatment: Modulation of Host Antitumor Directed Immune Responses by IL-4 and IL-12 in Renal Cell Cancer 161
B Cytokines/Adoptive Immunotherapy 175
16 Interleukin 12: Biology and Preclinical Studies of a New Anti-Tumor Cytokine 177
17 Cytokine Therapy of Metastatic Renal Cell Carcinoma: The Cleveland Clinic Experience
18 The Use of Cytokines, Tumor Infiltrating Lymphocytes, and Gene Therapy in the Treatment of Advanced Renal Cell Carcinoma: The UCLA Experience 204
19 Inhalational Interleukin-2 in the Treatment of Pulmonary Metastases in Patients with Renal Cell Carcinoma 210
20 Combination Immunotherapy with Interleukin-2 (IL-2), Alpha-Interferon ([alpha]IFN), and Autologous IL-2-Activated Lymphocytes (LAK) in Metastatic Renal Cell Cancer 224
21 T Cell Therapy of Patients with Advanced Renal Cell Carcinoma 235
22 Adoptive Immunotherapy with Interleukin-2 and LAK Cells or Gene Modified TIL in Patients with Renal Cell Carcinoma: Clinical and Laboratory Data 249
C Monoclonal Antibodies 255
23 Antibody Localization in Human Renal Cell Carcinoma: A Phase I Study of Monoclonal Antibody G250
Index 269